Svitlana Tatulych

  • Citations Per Year
Learn More
BACKGROUND Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated. OBJECTIVE We sought to(More)
BACKGROUND Tofacitinib is an oral Janus kinase inhibitor that improves clinical measures of psoriasis. OBJECTIVE We sought to assess patient-reported outcomes in tofacitinib-treated patients with(More)
BACKGROUND Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. OBJECTIVES We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to(More)
BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of(More)
  • 1